Savara (SVRA) Short term Debt (2015 - 2022)

Savara (SVRA) posted quarterly Short term Debt of $12.5 million for Q1 2022, up 50.01% quarter-over-quarter from $8.3 million in Q4 2021.

Savara (SVRA) Short term Debt (2015 - 2022) Analysis & Trends

Savara (SVRA) has reported Short term Debt for 7 consecutive years, with $12.5 million the latest figure, recorded in Q1 2022.

In Q1 2022, Short term Debt changed N/A year-over-year to $12.5 million; the TTM figure through Mar 2022 stood at $12.5 million (changed N/A YoY), while the FY2021 annual figure was $8.3 million, changed N/A from the prior year.
Short term Debt improved to $12.5 million in Q1 2022 per SVRA's latest filing, from $8.3 million in the prior quarter.
Across five years, Short term Debt topped out at $12.5 million in Q1 2022 and bottomed at $1.9 million in Q2 2018.
Historically, Short term Debt has averaged $5.4 million across 4 years, with a median of $4.0 million in 2018.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn
4	Revolution Medicines	43.64 Bn	43.64 Bn	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn
7	Royalty Pharma	33.72 Bn	35.84 Bn	-
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn
10	Savara	1.11 Bn	1.11 Bn	-

Download Data